# A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

Source: https://onco.cc/trials/nct04988295/  
OnCo record `nct04988295` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Lazertinib, Amivantamab, Pemetrexed and Carboplatin in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure is a phase 3 interventional study registered as NCT04988295 by Janssen Research & Development, LLC, with 776 participants enrolled, started 2021-11-17 and due to reach its primary completion in 2023-07-10. Interventions recorded: Lazertinib, Amivantamab, Pemetrexed and Carboplatin. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: MARIPOSA-2
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04988295
- Phase: 3
- Setting: A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 776
- Outcomes: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months vs Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months

## Sources

- ClinicalTrials.gov NCT04988295: https://clinicaltrials.gov/study/NCT04988295

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Amivantamab](https://onco.cc/drugs/amivantamab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Lazertinib](https://onco.cc/drugs/lazertinib/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct04988295.json